Selective Inhibitors of COX-2 - Are They Safe for the Stomach?

References

• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231: 232–5.
   PubMedGoogle Scholar
• Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expersison into transcriptional and translational phases. Proc Natl Acad Sci 1989;86:1657–61.
   Google Scholar
• Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644–8.
   PubMed Web of Science ®Google Scholar
• Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24 Suppl 49:6–8.
   PubMed Web of Science ®Google Scholar
• Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van den Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063–73.
   PubMed Web of Science ®Google Scholar
• Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable on NSAIDs. Gastroenterol Clin North Am 1996;25:373–96.
   PubMed Web of Science ®Google Scholar
• Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213–22.
   PubMed Web of Science ®Google Scholar
• Simon LS. Actions and toxic effects of the nonsteroidal antiinflammatory drugs. Curr Opin Rheumatol 1994;6:238–51.
   PubMedGoogle Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105(1B):31S–8S.
   Google Scholar
• Graham DY, Aqrawal NW, Roth SM. Prevention of NSAID- induced gastric ulcer with misoprostal: multicentre, doubleblind placebo-controlled trail. Lancet 1988;ii:1277–80.
   Google Scholar
• Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241–9.
   PubMed Web of Science ®Google Scholar
• Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527–32.
   PubMed Web of Science ®Google Scholar
• Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case- control study. Gastroenterology 1999;116:1305–9.
   PubMed Web of Science ®Google Scholar
• Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095–105.
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999;282:1921–8.
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106–11.
   PubMed Web of Science ®Google Scholar
• Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776–83.
   PubMed Web of Science ®Google Scholar
• Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of ‘rofecoxib’ (a cyclo-oxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis—a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43: 370–7.
   Google Scholar
• Goldstein JL, Agrawal NM, Silverstein F, Kaiser J, Burr AM, Verburg KM, et al. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs. Gastroenterology 1999;116:A174.
   Web of Science ®Google Scholar
• Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;20:1929–33.
   Web of Science ®Google Scholar
• Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celcoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124–32.
   PubMed Web of Science ®Google Scholar
• Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612–20.
   PubMed Web of Science ®Google Scholar
• Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS 1999;457:475–7.
   PubMed Web of Science ®Google Scholar
• Evans JMM, McMahon AD, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital due to inflammatory bowel disease. Gut 1997;40:619–22.
   PubMed Web of Science ®Google Scholar
• Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, et al. Upper gastrointestinal tolerability of celcoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol. 2000. p. in press.
   Google Scholar
• Dubois R, Giardiello FM, Smalley W. Nonsteroidal antiinflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773–91.
   PubMed Web of Science ®Google Scholar
• Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409–12.
   PubMed Web of Science ®Google Scholar